The outcomes (including annual exacerbation rate, the pre-bronchodilator FEV1, the health-related quality of life, and the severe adverse events) of anti-IL-5 therapy on eosinophilic COPD or asthma are listed in Table 2. This evidence concerns the gene IL5 and asthma.